Jonathan Miller

“Thanks so much for taking the question, and congrats on getting this deal closed and really showing us what you mean when you were talking about transitioning the business model in the last year.”

“A couple more about what we're expecting in October. In the second line cohort, can you remind us how much prior Lenvima those patients have gotten? Terry, to your point, not all TKIs are created equal, and we know that sequencing has effects.”

“Your line is open. uh thanks for taking the question and congrats on the progress this quarter guys uh i'd like to follow up first on the polyqar um there'll be a couple of patients you said next year am i right to assume that we shouldn't expect to see good translation of degradation rates from healthy volunteers to…”

“I'd like to start with the AUC, which seems to be driving the delta and dystrophin from what we expected. And I'd love to get more color on why you think it didn't translate so neatly from healthy volunteers.”

“I'd like to start with the AUC, which seems to be driving the delta and dystrophin from what we expected. And I'd love to get more color on why you think it didn't translate so neatly from healthy volunteers.”